Metric Finance
LearnFAQ
LearnFAQ

Learn / NVST

NYSE: NVST

Envista Holdings (NVST) stock, explained like you're 5

Envista Holdings trades on the New York Stock Exchange under the ticker NVST. It is a mid cap company in the medical/dental instruments industry, part of the healthcare sector, with a market value of about 3.7 billion dollars.

Ticker
NVST
Exchange
New York Stock Exchange
Sector
Healthcare
Industry
Medical/Dental Instruments
Size
Mid cap, about 3.7 billion dollars

Is Envista Holdings a small, medium or large cap company?

No. Envista Holdings is a mid cap stock, not a large cap. Its market cap, which is the total value of all its shares, is about 3.7 billion dollars.

Here is how you can tell. Multiply the share price by the number of shares to get the market cap, then compare it to the usual sizes. Micro cap is under 300 million dollars, small cap is 300 million to 2 billion, mid cap is 2 to 10 billion, large cap is 10 billion and up, and mega cap is over 200 billion. Market caps move every day with the share price, so treat the number as a recent snapshot.

How Envista Holdings makes money

  • Selling medicines, medical devices or healthcare services.
  • Insurance premiums or hospital and clinic fees.
  • Research and licensing deals.

What moves NVST stock

  • Results from clinical trials and approvals from regulators.
  • Drug prices, insurance rules and government policy.
  • Patents running out and new competing treatments.

In the news lately

  • Baird Downgrades Envista Holdings to Neutral From Outperform, Price Target is $26 (Yahoo Finance)
  • Envista Holdings (NVST) Climbed Today, But What Is Driving Attention? (Simply Wall Street)
  • Price Driven Insight from (NVST) for Rule Based Strategy (Stock Traders Daily)
  • NVST vs. ABT: Which Stock Is the Better Value Option? (Yahoo Finance)
  • Envista (NVST) Stock May Look Fully Valued On Strong Q2 Earnings (Simply Wall Street)

Follow NVST in your daily brief

Each trading day at 5 PM ET we post what happened to Envista Holdings and why it matters, in simple words. Free.

Start my free brief

Key terms to know before you follow NVST

  • Market cap
  • P/E ratio
  • EPS (earnings per share)
  • Earnings report
  • Volatility

Questions about Envista Holdings stock

What does Envista Holdings do?

Envista Holdings trades on the New York Stock Exchange under the ticker NVST. It is a mid cap company in the medical/dental instruments industry, part of the healthcare sector, with a market value of about 3.7 billion dollars.

What is the ticker symbol for Envista Holdings?

Envista Holdings trades under the ticker NVST on the New York Stock Exchange.

What is Envista Holdings's market cap?

Envista Holdings is a mid cap stock with a market cap of about 3.7 billion dollars.

How does Envista Holdings make money?

Selling medicines, medical devices or healthcare services. Insurance premiums or hospital and clinic fees. Research and licensing deals.

What moves NVST stock?

Results from clinical trials and approvals from regulators. Drug prices, insurance rules and government policy. Patents running out and new competing treatments.

How can I follow NVST stock every day?

Add NVST to your watchlist on Metric Finance. We post a free brief every trading day at 5 PM ET that explains what happened to the stocks you follow, in simple words.

Follow NVST daily

A free brief on Envista Holdings and your other stocks, every trading day at 5 PM ET.

Start my free brief

Similar stocks

  • SYK · Stryker
  • BDX · Becton Dickinson & co
  • MDLN · Medline
  • RMD · Resmed

Similar stocks

  • SYKStryker
  • BDXBecton Dickinson & co
  • MDLNMedline
  • RMDResmed

Compare NVST: NVST vs SYK, NVST vs BDX, NVST vs MDLN

Educational information, not financial advice. This guide explains the business in general terms and does not include live prices.

Metric Finance

Stocks explained like you're 5.

Product

  • Learn
  • FAQ
  • Your account

Legal

  • Privacy
  • Terms

Support

  • Contact
  • Unsubscribe

© 2026 Metric Finance

Built by Yashna & Vansh · Not investment advice · Market data may be delayed